Skip to content

What We Treat

FDA Advisory Committee to Review Cell Therapy for Duchenne Muscular Dystrophy

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meets July 29 to review Capricor Therapeutics’ deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy. The meeting comes ahead of an August 22 target decision date and follows a prior rejection of the company’s first application.

Table of Contents

  • What’s Happening
  • How Deramiocel Works
  • What the Data Show
  • Why This Matters
  • Conclusion

What’s Happening

On July 29, 2026, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee will convene to review Capricor Therapeutics’ Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The Federal Register notice confirming the meeting’s final details was amended on July 24, 2026, and the session will be livestreamed for public viewing.

This is Capricor’s second attempt at approval. The FDA rejected the company’s original application, based primarily on Phase 2 data, with a complete response letter citing substantial-evidence and manufacturing (CMC) deficiencies. The agency has since rescinded that letter and is now reviewing a resubmitted application built on additional Phase 3 data, with a PDUFA target action date of August 22, 2026.

How Deramiocel Works

Deramiocel (also known as CAP-1002) is an allogeneic, off-the-shelf cell therapy made from human cardiosphere-derived cells. Administered by infusion, it’s designed to reduce inflammation and support tissue repair in both skeletal and cardiac muscle — the two systems progressively damaged by DMD. If approved, it would be the first therapy to address both the skeletal and cardiac manifestations of the disease in a single product, a distinction that matters given that cardiomyopathy is a leading cause of death in DMD patients.

Deramiocel holds Orphan Drug designation in both the US and EU, Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations in the US, and Advanced Therapy Medicinal Product (ATMP) status in the EU — the last of which may qualify Capricor for a Priority Review Voucher if approved.

What the Data Show

The resubmitted BLA is supported by the Phase 2 HOPE-2 trial and its long-term HOPE-2-OLE extension, along with topline results from the Phase 3 HOPE-3 trial. HOPE-2 showed a 36.2% benefit on a mid-level elbow measure of upper limb function (PUL) versus placebo at 12 months, along with reduced cardiac injury markers (CK-MB and total CK), suggesting less myocardial damage.

HOPE-3 met its primary endpoint, showing a 54% slowing of disease progression on the PUL v2.0 scale, and its key cardiac endpoint showed a 91% slowing in the decline of left ventricular ejection fraction (LVEF) by central cardiac MRI — a marker of heart muscle function. The trial also met additional controlled secondary endpoints.

Why This Matters

For the regenerative and integrative medicine community, this advisory committee meeting is a bellwether moment for cell therapy in a devastating pediatric disease with no treatment that addresses both its muscular and cardiac components. An advisory committee’s recommendation isn’t binding, but it heavily influences the FDA’s final decision and signals how regulators are weighing benefit-risk tradeoffs for allogeneic cell products more broadly. A second look at a previously rejected application, now backed by Phase 3 data, also illustrates how sponsors are increasingly able to iterate through FDA’s regenerative medicine pathways rather than face a single make-or-break review.

Conclusion

The July 29 advisory committee meeting is a critical checkpoint on deramiocel’s path to potential approval by August 22. A positive recommendation would move a first-in-class dual-benefit cell therapy closer to patients; a negative one would raise fresh questions about the regulatory bar for allogeneic cell products in rare pediatric disease.

Sources

  • NeurologyLive, “FDA Advisory Committee Schedules Meeting to Review Deramiocel’s BLA in Duchenne Muscular Dystrophy” — Read here
  • GlobeNewswire / Capricor Therapeutics, “Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy” — Read here
  • Federal Register, “Cellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice” — Read here

FDA Approves Tregzi, First Regulatory T-Cell Therapy to Reduce Chronic GVHD

The FDA has approved Tregzi, a precision-engineered cell therapy from Orca Bio, as the first regulatory T-cell (Treg) based treatment for adults undergoing allogeneic stem cell transplants for blood cancers. Trial data showed it more than doubled one-year survival free of chronic graft-versus-host disease compared with standard transplants.

Table of Contents

  • What Happened
  • How Tregzi Works
  • What the Data Show
  • Why This Matters
  • Conclusion

What Happened

On June 30, 2026, the FDA approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), developed by Orca Bio and previously known as Orca-T. It is indicated for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (GVHD)-free survival in adults with hematologic malignancies. The approval makes Tregzi the first FDA-cleared therapy built on highly purified regulatory T cells, and only the second cell therapy ever approved specifically in the GVHD setting, following Mesoblast’s Ryoncil.

Tregzi received Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations ahead of filing, along with Priority Review. The FDA’s target action date was extended from April to July 2026 after the agency requested additional manufacturing information.

How Tregzi Works

Tregzi reformulates a standard allogeneic stem cell transplant rather than replacing it outright. Instead of infusing an unmodified mix of stem and immune cells from a matched donor, it separates the donor material into components: hematopoietic stem and progenitor cells to rebuild the patient’s blood and immune system, highly purified regulatory T cells to suppress the immune attack that causes GVHD, and a follow-up dose of conventional T cells to help clear residual cancer cells. The goal is to preserve the beneficial graft-versus-leukemia effect of a transplant while reducing the collateral immune damage that has long made GVHD one of the field’s most difficult trade-offs.

What the Data Show

Approval was based on the Phase 3 PRECISION-T trial, a randomized, open-label study of 187 adults with blood cancers, including acute leukemia and myelodysplastic syndrome, across 19 transplant centers. Patients received either Tregzi with single-agent tacrolimus, or a standard transplant with a combination of tacrolimus and methotrexate.

At one year, 78.0% of Tregzi recipients achieved chronic GVHD-free survival, compared with 38.4% in the standard transplant group. After accounting for death as a competing risk, serious chronic GVHD developed in 12.6% of Tregzi patients versus 44.0% of controls. Safety data also favored Tregzi: Grade 3 or 4 acute GVHD at day 180 occurred in 6% of Tregzi recipients versus 10% with standard transplant, alongside fewer serious infections.

Why This Matters<

Beyond Mold: A Complete Guide to Biotoxin Illness (CIRS) and How to Recover

Close-up of a weathered wall with cracks and green algae, texture details.

If you have spent months or years cycling through specialists, collecting vague diagnoses like fibromyalgia or chronic fatigue syndrome, and feeling as though your body has become a stranger to you, you are not alone. You may be dealing with Biotoxin Illness/CIRS, a condition rooted in a genetic quirk that affects roughly 25 percent of the population. The experience is often isolating and frightening, but the science behind it is clear, and effective treatment exists. In humid regions like Florida, where water-damaged buildings are distressingly common, understanding this condition is not just academic; it is a practical necessity for reclaiming your health.

Table of Contents

What Is Biotoxin Illness (CIRS)? The 25% Problem

Chronic Inflammatory Response Syndrome (CIRS) is not a simple mold allergy. It is a multi-system, multi-symptom inflammatory illness driven by a genetic susceptibility in the immune system. Specifically, about one in four people carry certain HLA-DR genotypes that prevent their immune cells from effectively recognizing and clearing biotoxins from the body. When a genetically susceptible person is exposed to a biotoxin, their innate immune system launches a chronic, unrelenting inflammatory response. The toxin is never properly tagged for removal, so it remains in the tissues, keeping the body in a state of low-grade, systemic fire.

The triggers for this cascade are broader than many people realize. The most common culprit is mold and mycotoxins from water-damaged buildings, but the list also includes the bacteria responsible for Lyme disease (Borrelia burgdorferi), dinoflagellates like those causing ciguatera poisoning from reef fish, and other environmental contaminants. This is not a respiratory condition limited to sneezing and wheezing. CIRS is a whole-body inflammatory illness that can disrupt nearly every system, from neurological function to hormone production.

The 37 Symptoms: Why You Feel So Terrible

One of the most bewildering aspects of CIRS is the sheer number and variety of symptoms it can produce. The condition is associated with 37 or more symptoms, which researchers have organized into 13 distinct clusters. If a person exhibits symptoms in eight of those 13 clusters, CIRS becomes a strong diagnostic possibility. This is not a condition that announces itself with a single, clear sign; it is a storm that hits from multiple directions at once.

The most debilitating symptoms often include profound brain fog, memory loss, and difficulty concentrating. Physical symptoms can range from crushing fatigue and joint pain without visible swelling to unusual sensations like static shocks when touching metal or “ice pick” pains that come and go without warning. Chronic sinus congestion, shortness of breath, and a persistent cough are also common. Because these symptoms span so many medical specialties, patients often find themselves shuffled from neurologist to rheumatologist to psychiatrist, with no one connecting the dots.

This fragmentation leads to what many patients describe as medical gaslighting. Standard lab panels, including complete blood counts, comprehensive metabolic profiles, and autoimmune markers, typically return normal. When the tests are normal but the patient is clearly suffering, the default explanation is too often anxiety, depression, or a psychosomatic disorder. If you have been told “it’s all in your head,” the science of CIRS says it is actually in your cells, driven by a measurable inflammatory cascade that standard labs are not designed to detect.

How Is CIRS Diagnosed? The Specific Biomarker Panel

Because standard blood work is essentially useless for identifying CIRS, diagnosis requires a targeted functional medicine panel based on the Shoemaker protocol. This is not about guessing; it is about measuring the specific inflammatory and hormonal markers that become dysregulated in this condition. The critical biomarkers include melanocyte-stimulating hormone (MSH), which is typically low; vasoactive intestinal polypeptide (VIP), also low; antidiuretic hormone (ADH), often low; transforming growth factor beta-1 (TGF-beta 1), which runs high; matrix metalloproteinase-9 (MMP-9), high; vascular endothelial growth factor (VEGF), low; and complement C4a, which is markedly elevated. This pattern of highs and lows paints a clear picture of a body stuck in a chronic inflammatory state.

Beyond blood work, there is a simple, inexpensive screening tool called the Visual Contrast Sensitivity (VCS) test. This test measures your ability to detect subtle differences in shades of gray, a neurological function that is often impaired by neurotoxins. It is not a definitive diagnostic tool on its own, but it is an excellent way to track the severity of neuroinflammation and monitor progress during treatment.

Another critical piece of the diagnostic puzzle is a nasal swab to check for Multiple Antibiotic Resistant Coagulase Negative Staphylococci, or MARCoNS. This resistant staph infection colonizes the deep nasal passages in many CIRS patients and actively suppresses MSH production, perpetuating the illness. Identifying and eradicating MARCoNS is a non-negotiable step before the final phase of treatment can begin. At INTEGRAL Medicine, we use the full Shoemaker protocol biomarker panel to get you answers, not guesses.

The Treatment Roadmap: From Source Removal to VIP

Treating CIRS is a methodical, step-by-step process. Skipping steps or rushing to the finish line almost always backfires. The protocol is designed to remove the source of the toxins, bind and eliminate the circulating toxins, clear any secondary infections, and finally repair the damage done to the brain and endocrine system.

Step 1: Source Removal (The Non-Negotiable)

You cannot heal while living or working in a water-damaged building. Studies suggest that up to 50 percent of buildings in the United States have some degree of water damage, making this a widespread and often hidden problem. The first and most critical step is to identify and either remediate or leave the contaminated environment. Practical steps include running an ERMI (Environmental Relative Moldiness Index) dust test on your home, hiring a qualified professional for a thorough mold inspection, and addressing the root causes of moisture intrusion. For those wondering how to get rid of mycotoxins in a home, the checklist includes repairing all leaks, maintaining indoor humidity below 50 percent with dehumidifiers, using HEPA air filters, and properly cleaning or discarding porous items that cannot be fully remediated.

Step 2: Binding and Elimination (The Shoemaker Protocol)

Once you are in a clean environment, the next phase focuses on pulling biotoxins out of the body. This is done with binders, substances that attach to toxins in the gut and prevent them from being reabsorbed. The gold standard binder is cholestyramine (CSM), a prescription medication, but activated charcoal, bentonite clay, and other natural binders are also used depending on the patient’s tolerance and needs.

A more advanced approach involves what is known as the lipid-exchange method. Because biotoxins are lipophilic, meaning they store themselves in fatty tissues, simply binding toxins in the gut is sometimes not enough. Using agents like phosphatidylcholine and specific fatty acids helps mobilize stored toxins from fat cells so they can be bound and eliminated. This addresses a common question: how long do mycotoxins stay in the body? The answer varies based on genetics, the total toxic load, and treatment compliance, but active binding and mobilization typically continue for six to eighteen months before the body’s burden is sufficiently reduced.

Step 3: Nasal Treatment (MARCoNS Eradication)

Before the body can truly begin to repair, the MARCoNS infection must be addressed. This typically involves a compounded nasal spray, often containing Bactroban, EDTA, and gentamicin (known as BEG spray), which is used for several weeks. This step is crucial because MARCoNS produces a biofilm in the nasal passages and actively suppresses MSH, a master hormone that regulates inflammation, sleep, and pain perception. Leaving MARCoNS untreated will block the neuroendocrine repair that is the ultimate goal of treatment.

Step 4: VIP Spray (The Repair Phase)

The final step in the core protocol is the use of Vasoactive Intestinal Polypeptide (VIP), a naturally occurring neuropeptide. In CIRS, VIP levels are typically very low. Replacing VIP with a prescription nasal spray helps repair the blood-brain barrier, restore normal sleep architecture, normalize hormone levels, and reduce the chronic inflammatory response. A critical caution: VIP should never be used until the source has been removed, binders have reduced the toxin load, and MARCoNS has been eradicated. Using it too early can actually worsen symptoms by mobilizing toxins in a body that is not yet ready to clear them.

Beyond the Protocol: Advanced Therapies for Stubborn Cases

For many patients, the Shoemaker protocol is life-changing. But some individuals, particularly those with very high toxic loads, long exposure histories, or additional complicating factors, need a deeper toolkit. This is where an integrative approach becomes essential. Advanced modalities can include ozone therapy to modulate the immune system and improve oxygen utilization, far infrared sauna to enhance detoxification through sweating, and Low-Dose Immunotherapy (LDI) to retrain the immune system’s overactive response to triggers.

Another often-overlooked factor is the role of implanted materials and chronic infections. Dental implants, root canals, or even old surgical mesh can act as reservoirs for biotoxins or trigger a cross-reactive inflammatory response. Similarly, chronic viral infections like Epstein-Barr, Herpes, or an overgrowth of Candida can keep the immune system in a state of perpetual alarm, mimicking or compounding CIRS. The CranioBiotic Technique (CBT) is another tool for addressing these hidden stressors. If you have tried the standard protocol and still feel stuck, we have a deeper toolkit. We do not give up on you.

What Is the Prognosis? Can You Fully Recover?

Honest conversations about outcomes are important. CIRS is a chronic condition that requires ongoing awareness and management, much like managing an autoimmune disease. The goal is not necessarily a permanent “cure” in the sense that you can return to a moldy building without consequence. However, with proper treatment, the vast majority of patients see a 70 to 90 percent improvement in their quality of life. The recovery timeline is variable, typically ranging from six months to two years for significant improvement, depending on the severity and duration of the exposure and the individual’s genetic makeup. Long-term management involves avoiding re-exposure, periodic VCS testing to catch any early signs of relapse, and possibly using binders intermittently after known or suspected exposures.

Frequently Asked Questions About Biotoxin Illness/CIRS

Is CIRS a real disease? This question arises because CIRS is still gaining recognition in mainstream medicine. The answer is yes. The Shoemaker protocol is built on decades of peer-reviewed research, and the CDC acknowledges the serious health effects of mold exposure in water-damaged buildings. The specific biomarkers and treatment steps are well-documented in the scientific literature.

Can I treat CIRS without leaving my home? No. If your home is the source of the biotoxins, source removal is mandatory. This may mean a temporary relocation during remediation or, in severe cases, a permanent move. There is no binder or supplement that can outrun a continuously contaminated environment.

Does insurance cover CIRS treatment? This is a significant challenge. While some office visits and standard labs may be covered, many of the specialized biomarker tests and compounded medications are not fully reimbursed by insurance. We encourage you to schedule a consultation to discuss your specific situation and explore financial options transparently.

Can children get CIRS? Yes, children are absolutely susceptible, though their symptoms may look different. In pediatric cases, CIRS can present as behavioral issues, ADHD-like symptoms, chronic ear infections, or developmental delays. The same principles of diagnosis and treatment apply, though the approach is modified for a child’s physiology.

Why Choose INTEGRAL Medicine for CIRS Treatment?

Living in the Sarasota and Bradenton area means living with high humidity and a built environment that is uniquely vulnerable to water damage. We understand the specific environmental triggers of this region and how they contribute to Biotoxin Illness/CIRS. Our approach combines the rigorous, evidence-based Shoemaker protocol with advanced functional medicine therapies like ozone, sauna, and LDI to address even the most stubborn cases. Most importantly, we listen to your story with warmth and respect. We know your symptoms are real, and we have the tools to help. Schedule a consultation today to start your biomarker testing and get your life back.

Medical Ozone Therapy for Chronic Fatigue: Energy Restoration

 

A medical professional in a white coat examines a clipboard with patient documents.

If you are living with chronic fatigue that rest cannot fix, you know the difference between being tired and being depleted. The exhaustion that defines myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is not the kind you can sleep off. It is a profound, cellular collapse that steals your ability to work, socialize, and sometimes even get out of bed. For the estimated 3.3 million Americans affected by this condition, the search for answers often becomes a full-time job in itself, one made harder by the fact that more than 9 in 10 people with ME/CFS have never received a formal diagnosis. At INTEGRAL Medicine, we see you. And in 2026, there is a regenerative approach gaining traction that deserves a closer look: medical ozone therapy.

Table of Contents

What Is ME/CFS? Understanding the Condition Beyond Exhaustion

ME/CFS is a complex, multi-system neuroimmune disease. It is not a psychological condition, a character flaw, or simple burnout, though patients are often made to feel otherwise. The Centers for Disease Control and Prevention (CDC) recognizes ME/CFS as a serious, long-term illness that affects multiple body systems, yet the path to diagnosis remains frustratingly indirect.

The hallmark symptom that separates ME/CFS from general fatigue is post-exertional malaise, or PEM. PEM is a crash in physical, cognitive, or emotional function that occurs after even minor exertion and does not resolve with rest. Someone with ME/CFS might take a short walk on Monday and find themselves bedbound on Wednesday, their body unable to recover from what should have been a trivial demand.

Diagnosis requires severe fatigue lasting at least six months, accompanied by one of two additional symptoms: cognitive impairment, often described as brain fog, or orthostatic intolerance, where symptoms worsen upon standing upright. These criteria, established by the Institute of Medicine, provide a clinical framework, but there is no single lab test to confirm the condition. Diagnosis is a process of exclusion, ruling out other illnesses one by one. Women are diagnosed two to four times more often than men, and the condition most commonly affects young to middle-aged adults, though it can strike at any age.

Why Conventional Medicine Often Falls Short

For a disease that costs the U.S. economy an estimated $18 to $51 billion annually in medical costs and lost income, the treatment landscape remains starkly inadequate. No FDA-approved cure exists. Standard care focuses on symptom management: antidepressants for mood, sleep aids for unrefreshing sleep, and activity pacing to avoid crashes. These tools can help some patients cope, but they do not address the underlying biology driving the illness.

The diagnostic gap compounds the problem. With more than 9 in 10 people undiagnosed, millions suffer without a treatment plan or even the validation that their condition is real. Many patients report being dismissed by physicians who attribute their symptoms to stress, depression, or deconditioning. This dismissal delays care for years, sometimes decades, and deepens the isolation that already accompanies a life-limiting illness. The economic burden reflects not only lost productivity but the high cost of trial-and-error medicine that rarely delivers meaningful recovery.

Medical Ozone Therapy: A New Mechanism for Cellular Energy

Medical ozone therapy is not a fringe experiment. It is a regulated medical procedure used for decades in European integrative medicine, and it is now gaining attention in the United States as research expands into its mechanisms and applications. The therapy involves administering a precise mixture of medical-grade ozone and oxygen to stimulate the body’s own healing and regenerative pathways.

At the cellular level, ozone improves oxygen utilization. This is critically relevant for ME/CFS patients because many exhibit impaired energy metabolism. The Mayo Clinic has noted that some people with ME/CFS have difficulty converting fats and sugars into usable energy, leaving cells starved for fuel even when nutrients are available. Ozone therapy supports mitochondrial function, the engine inside every cell responsible for energy production. By enhancing the efficiency of that engine, ozone helps the body generate more ATP, the molecule that powers everything from muscle contraction to cognitive processing.

Ozone also modulates the immune system. Chronic inflammation and viral reactivation, including Epstein-Barr virus and other latent pathogens, are suspected drivers of ME/CFS. Ozone has the ability to downregulate excessive inflammatory responses while stimulating the immune system to address lingering infections. This dual action, calming the storm while clearing the triggers, makes it uniquely suited to a condition with both immune dysfunction and inflammatory features.

Common administration methods include major autohemotherapy, or MAH, where a small amount of blood is drawn, mixed with ozone, and reinfused, and rectal insufflation, which delivers ozone gas through the intestinal mucosa. Both are performed under clinical supervision with medical-grade equipment.

How Ozone Therapy Addresses the Root Causes of Chronic Fatigue

The lived experience of ME/CFS is one of heavy limbs, mental fog, and the constant threat of a crash. Ozone therapy targets the physiological underpinnings of these symptoms in ways that symptom-managing drugs cannot.

By improving microcirculation and the flexibility of red blood cells, ozone delivers more oxygen to tissues throughout the body. This can reduce the sensation of heaviness in the arms and legs and sharpen cognitive clarity. Patients often describe the effect as a lifting of the fog, sometimes within the first few sessions.

Ozone’s anti-inflammatory properties help lower the cytokine surges that contribute to post-exertional malaise. When the immune system overreacts to a minor stressor, it floods the body with inflammatory signals that amplify fatigue, pain, and cognitive dysfunction. Ozone helps recalibrate that response, raising the threshold for what triggers a crash.

Sleep quality and pain levels are two of the most debilitating aspects of ME/CFS, and both can improve with a series of ozone treatments. Unlike pharmaceuticals that mask symptoms while often adding side effects, ozone therapy aims to restore the body’s baseline capacity for energy production and self-regulation. The goal is not just to feel better temporarily but to rebuild the foundation from which healing can occur.

What to Expect from Ozone Therapy for ME/CFS

Ozone therapy is not a one-session miracle. Treatment is typically delivered in a series, often six to twelve initial sessions, with benefits accumulating gradually over time. The body is being retrained at a cellular level, and that process takes repetition and patience.

Some patients experience a temporary healing crisis during the early phase of treatment. This can include mild flu-like symptoms, fatigue, or headache as the body mobilizes toxins and adjusts to increased oxygen utilization. This reaction is normal, typically short-lived, and managed by your clinician through adjustments to dosing and session frequency.

Ozone therapy works best as part of a comprehensive approach. At INTEGRAL Medicine, we integrate treatment with lifestyle support that honors the energy limitations of ME/CFS: pacing strategies that prevent crashes, nutrition that reduces inflammatory load, sleep hygiene that protects circadian rhythms, and stress management techniques that calm an overactive nervous system. Each protocol is personalized based on your lab work, symptom profile, and individual tolerance.

Results vary, as they do with any treatment for a condition as heterogeneous as ME/CFS. Some patients regain 50 to 70 percent of their pre-illness energy levels and resume activities they had long abandoned. Others experience more modest but still meaningful improvements in pain, sleep, and cognitive function. The measure of success is not a return to who you were before illness but a reclaiming of quality of life on your own terms.

Is Medical Ozone Therapy Safe? Addressing Common Concerns

When administered by trained professionals using medical-grade equipment, ozone therapy has an excellent safety profile. Side effects are typically mild and transient, limited to temporary discomfort at the infusion site or the short-lived detox symptoms described above.

There are contraindications that every responsible clinician screens for before initiating treatment. These include G6PD deficiency, also known as favism, a genetic condition that affects red blood cell stability; pregnancy; and active, uncontrolled hyperthyroidism. A thorough intake and appropriate lab work ensure that ozone therapy is appropriate for your specific case.

Ozone therapy is not a replacement for emergency medical care or for the management of acute, life-threatening conditions. It is a complementary, regenerative approach designed for chronic illness where conventional options have fallen short. The therapy has been used safely in European clinics for decades, and the growing body of research in the United States is now bringing this option to patients who have been waiting for something beyond symptom suppression.

Chronic Fatigue vs. Long COVID: Why Ozone Therapy Works for Both

The overlap between Long COVID and ME/CFS is impossible to ignore in 2026. Both conditions share core mechanisms: mitochondrial dysfunction, immune dysregulation, and persistent inflammation that refuses to resolve. Many Long COVID patients meet the diagnostic criteria for ME/CFS, and the two conditions are increasingly understood as post-viral syndromes with common roots.

Ozone therapy has shown promise in early clinical applications for Long COVID fatigue, and the same mechanisms that make it relevant for ME/CFS apply here. Improved oxygen delivery, immune modulation, and anti-inflammatory effects address the biology driving both conditions. For patients who developed chronic fatigue after a viral infection, whether Epstein-Barr, COVID-19, Lyme disease, or another pathogen, ozone’s antiviral properties add another layer of therapeutic potential.

This overlap means that patients who are unsure whether they have ME/CFS, Long COVID, or some combination of both can still find a treatment path that addresses the underlying dysfunction. The diagnostic label matters less than the biological reality, and ozone therapy targets that reality directly.

Your Next Step: Finding Relief in Sarasota and Bradenton

At INTEGRAL Medicine, we specialize in regenerative therapies for complex chronic conditions, including ME/CFS, fibromyalgia, and Long COVID. We understand that many of our patients arrive after years of being dismissed, their symptoms minimized, their suffering unseen. Our clinic provides a compassionate, judgment-free environment where your experience is believed and your treatment plan is built around your unique needs.

We offer free 15-minute discovery calls to determine if ozone therapy is right for your specific case. Treatment plans are transparently priced, and we work with patients to create manageable protocols that fit within their energy budget. We serve the Sarasota and Bradenton communities with the conviction that healing is possible, even when conventional medicine has offered little hope.

Frequently Asked Questions About Ozone Therapy for Chronic Fatigue

How long does it take to see results from ozone therapy?

Most patients notice improvements in energy and mental clarity after four to six sessions, with full benefits emerging after eight to twelve sessions. The timeline varies depending on the severity and duration of illness, as well as individual responsiveness.

Can ozone therapy cure chronic fatigue syndrome?

There is no known cure for ME/CFS at this time. However, ozone therapy can significantly reduce symptom severity and improve quality of life for many patients. The goal is meaningful recovery of function, not a claim of complete eradication.

Is ozone therapy covered by insurance?

Ozone therapy is typically not covered by insurance, as it falls outside standard conventional care models. We offer flexible payment plans and accept HSA and FSA funds to make treatment accessible.

What is the difference between ozone therapy and hyperbaric oxygen therapy?

Ozone therapy uses a reactive form of oxygen to stimulate immune and metabolic pathways, while hyperbaric oxygen therapy uses pressurized pure oxygen to saturate tissues. Both can be helpful for chronic conditions, but they target different mechanisms. Ozone’s immune-modulating and mitochondrial effects make it particularly relevant for ME/CFS.

Is ozone therapy painful?

Most patients tolerate treatment well. Major autohemotherapy involves a standard blood draw, similar to giving a blood sample. Rectal insufflation is generally painless. Any discomfort is brief and managed by your clinician.

References and Further Reading

CDC: ME/CFS Basics and Statistics
Mayo Clinic: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Overview
Cedars-Sinai: Diagnostic Criteria for ME/CFS
National Academy of Medicine: Institute of Medicine Diagnostic Guidelines
Emerging Research on Ozone Therapy for Chronic Fatigue and Long COVID (PubMed/PMC)

Interstitial Cystitis vs. UTI: How Platelet-Rich Plasma (PRP) and Ozone Therapy Offer New Hope for Lasting Relief

Minimalist graphic illustration of the female reproductive system in shades of pink on a white background.

If you have been told you have a UTI but antibiotics are not working, you may actually be dealing with Interstitial cystitis (IC) rather than a standard UTI. The two conditions share nearly identical symptoms, yet they demand fundamentally different treatment approaches. For the millions of Americans trapped in this diagnostic gray zone, the frustration is real: negative urine cultures, repeated doctor visits, and a growing sense that something deeper is wrong. This article clarifies the distinction between IC and UTI and introduces two regenerative therapies, Platelet-Rich Plasma and Ozone, that are changing how we treat chronic bladder pain at its source.

Table of Contents

The Chronic Confusion: Why IC/BPS Is Mistaken for a UTI

Interstitial cystitis, now formally called Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), is a chronic condition defined by bladder pressure, pelvic pain, and urinary urgency and frequency. Unlike a urinary tract infection, IC/BPS involves no active bacterial infection. It is a diagnosis of exclusion, meaning clinicians rule out other conditions, including UTIs, before arriving at the diagnosis. The Cleveland Clinic estimates that 1 to 4 million men and 3 to 8 million women in the United States live with IC/BPS. About 5 to 10 percent of cases are ulcerative, characterized by Hunner’s ulcers on the bladder wall, while roughly 90 percent are non-ulcerative, presenting with pinpoint bleeding called glomerulations.

A UTI, by contrast, is an acute bacterial invasion of the urinary tract, most commonly by E. coli. It triggers inflammation, burning, and urgency, symptoms that overlap almost perfectly with IC/BPS. The Mayo Clinic notes that some IC/BPS patients urinate up to 60 times a day, a frequency that mimics a severe infection. This symptom mirroring is the primary engine of misdiagnosis. A patient presents with classic UTI complaints, receives a short course of antibiotics, and may feel transient relief if inflammation temporarily subsides. But the symptoms return, and the cycle repeats.

The critical diagnostic gap lies in the urine culture. In a true UTI, bacteria grow in the lab. In IC/BPS, cultures come back negative. Yet many patients are treated empirically for months or years based on symptoms alone. This leads to unnecessary antibiotic exposure, disruption of the gut and vaginal microbiome, and delayed treatment for the real problem. The stakes rise when IC/BPS progresses. Cleveland Clinic defines Stage 4 IC/BPS as continuing symptoms for over two years, with bladder tissue hardening and reduced bladder capacity. Correct diagnosis is not just about relief; it is about preventing irreversible structural damage.

Why Conventional Treatments Fall Short

Standard care for IC/BPS typically begins with oral medications. Amitriptyline, a tricyclic antidepressant, is prescribed to modulate nerve pain but often brings sedation and dry mouth. Pentosan polysulfate sodium, known as Elmiron, was long used to repair the bladder lining, though concerns about retinal toxicity have curbed its use. Antihistamines like hydroxyzine target mast cell activity but offer partial relief at best. Bladder instillations, where solutions such as DMSO, heparin, or lidocaine are placed directly into the bladder, can soothe symptoms but require repeated clinic visits and do not rebuild tissue.

These approaches share a fundamental limitation: they manage symptoms without repairing the underlying damage. The bladder lining, specifically the glycosaminoglycan or GAG layer, acts as a protective barrier between urine and the bladder wall. In IC/BPS, this layer becomes compromised, allowing irritants in urine to penetrate and trigger nerve endings and mast cells. Medications may dampen the pain signal or reduce inflammation temporarily, but they do not regenerate the GAG layer or heal ulcerated tissue. This is the “Band-Aid” problem. Patients cycle through therapies, often with diminishing returns, while the structural defect persists.

Most major medical sources, including Mayo Clinic and Cleveland Clinic, do not cover regenerative or biologic therapies in depth. Their treatment algorithms stop at symptom suppression and, in rare cases, surgery. This leaves a significant gap for patients who want more than management. They want repair.

A New Frontier: Platelet-Rich Plasma (PRP) for Bladder Regeneration

How PRP Heals the Bladder Lining

Platelet-Rich Plasma therapy uses the patient’s own blood to concentrate platelets and the growth factors they contain. These growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-beta), are the body’s native signaling molecules for tissue repair. When PRP is instilled into the bladder, these proteins stimulate cellular proliferation, collagen synthesis, and angiogenesis, the formation of new blood vessels. The result is a regenerative environment that can rebuild the damaged GAG layer and heal Hunner’s ulcers in ulcerative IC.

The procedure is straightforward. A small sample of the patient’s blood is drawn and spun in a centrifuge to separate the platelet-rich fraction. This concentrate is then introduced into the bladder via a catheter, similar to a standard instillation. The patient holds the solution for a prescribed period, allowing the growth factors to contact the bladder wall. Unlike antibiotics for UTI, which target bacteria, PRP targets the structural defect. It addresses the reason the bladder hurts, not just the sensation of pain.

What the Research Says

Clinical research on PRP for IC/BPS has accelerated in recent years. By 2026, multiple studies have demonstrated significant reductions in pain scores, measured by the Visual Analog Scale (VAS), and improvements in voiding frequency following PRP therapy. One protocol involves a series of two to three treatments spaced several weeks apart, with cumulative benefits observed over three to six months. PRP is not a one-time fix but a process that mirrors the body’s own healing timeline.

The safety profile is a major advantage. Because PRP is autologous, derived from the patient’s own blood, there is no risk of allergic reaction or disease transmission. Side effects are typically limited to mild catheter-related discomfort or transient bladder irritation. This stands in stark contrast to the systemic side effects of oral medications or the invasiveness of surgical interventions like bladder augmentation or urinary diversion. For patients who have spent years on the treatment treadmill, PRP offers a biologically rational alternative.

Ozone Therapy: Calming the Inflammatory Storm

Ozone’s Dual Action: Antimicrobial and Anti-Inflammatory

Ozone therapy has a long history in European medicine and is gaining traction in the United States for its unique ability to modulate the immune system and combat low-grade infections. In the context of IC/BPS, ozone works through two primary mechanisms. First, it reduces mast cell activation. Mast cells are immune cells that release histamine and other inflammatory mediators, and their overactivity is a well-documented driver of IC pain. Ozone, administered via rectal insufflation or minor autohemotherapy, shifts the immune response toward a less reactive state, calming the inflammatory cascade that keeps the bladder in a state of hypersensitivity.

Second, ozone addresses a hidden contributor to chronic bladder symptoms: biofilm and low-grade bacterial persistence. Many IC/BPS patients have a history of recurrent UTIs. Even when standard urine cultures turn negative, bacterial fragments or biofilm communities can remain embedded in the bladder wall, below the detection threshold of conventional tests. Ozone is a powerful oxidant that disrupts biofilm matrices and neutralizes bacteria, viruses, and fungi. For patients whose symptoms began with a confirmed UTI and never fully resolved, ozone can clear the residual microbial debris that perpetuates inflammation.

A third benefit is improved oxygen utilization. Ozone therapy enhances the ability of red blood cells to deliver oxygen to tissues and stimulates mitochondrial function. In the pelvis, this means better oxygenation of the bladder wall, which supports healing and reduces the hypoxic stress that contributes to fibrosis in advanced IC/BPS.

Combining Ozone with PRP for Synergy

The most compelling treatment model combines ozone and PRP in a sequenced protocol. Ozone is used first to “clean the field.” It reduces the inflammatory burden, clears any lingering microbial presence, and improves tissue oxygenation. Once the bladder environment is stabilized, PRP is introduced to rebuild the GAG layer and heal structural damage. This dual approach addresses both the “infection mimic” that creates UTI-like symptoms and the “structural damage” that defines IC.

No top competitor source, not Mayo Clinic, Cleveland Clinic, nor Michigan Medicine, covers this combination. The standard model treats IC/BPS as a mystery to be managed. The regenerative model treats it as a wound to be healed. For patients who have been told there is nothing more to offer, this distinction matters.

A Practical Guide: Is This Treatment Right for You?

Ideal candidates for PRP and ozone therapy are patients with a confirmed diagnosis of IC/BPS, typically via cystoscopy, who have not responded adequately to conventional treatments. This includes those with Hunner’s ulcers and those with non-ulcerative IC. It also includes patients stuck in the “culture-negative UTI” loop, those who experience classic UTI symptoms but repeatedly test negative for infection. These individuals often have undiagnosed IC/BPS and may benefit from a regenerative approach.

This treatment is not for everyone. Anyone with an active, culture-confirmed bacterial UTI must have that infection treated with appropriate antibiotics first. Patients with severe bladder fibrosis and a capacity reduced to a few ounces, characteristic of end-stage IC, may have limited regenerative potential and should discuss realistic expectations during consultation. Pregnant or breastfeeding women should defer these therapies until a later date.

Results follow a predictable timeline. Ozone therapy often produces an immediate anti-inflammatory effect, with some patients reporting reduced pain and urgency within days. PRP works more slowly, with initial improvement typically noted at four to eight weeks as growth factors stimulate tissue repair. Maximum benefit is usually seen after a full series of treatments, around three to six months. Costs for PRP and ozone are generally out-of-pocket, as insurance coverage for regenerative therapies remains limited in 2026. A consultation at Biome can clarify candidacy, protocol design, and financial considerations.

Frequently Asked Questions

Can IC be cured, or is it just managed?

While IC/BPS is not considered curable in the traditional sense, PRP therapy shifts the goal from symptom suppression to tissue regeneration. By rebuilding the GAG layer and healing ulcers, it addresses the structural basis of the disease. Many patients achieve long-term remission that feels functionally like a cure, even if the underlying predisposition remains.

Is IC an autoimmune disease?

IC/BPS is not formally classified as autoimmune, but immune dysregulation plays a central role. Mast cell activation, in particular, drives much of the pain and inflammation. This is why ozone therapy, which modulates the immune response, is effective. It calms the specific immune pathways that are overactive in IC without broadly suppressing the immune system.

Can men get IC?

Yes. The Cleveland Clinic estimates that 1 to 4 million men in the United States have IC/BPS. In men, the condition is frequently misdiagnosed as chronic prostatitis or chronic pelvic pain syndrome. The PRP and ozone protocols discussed here are gender-neutral and can be applied to male patients with equal rationale.

What is the success rate of PRP for IC?

Early clinical data, current as of 2026, indicates that 60 to 80 percent of patients report significant symptom reduction following a full series of PRP treatments. Long-term durability data is still being collected, but the regenerative mechanism suggests that results can be sustained, particularly when combined with ozone and appropriate lifestyle modifications.

Take the Next Step: Beyond Antibiotics and Pain Pills

If you are caught in the “UTI vs. IC” loop, cycling through antibiotics that do not work and pain medications that only dull the edges, PRP and ozone therapy offer a path that addresses the root cause. These are not experimental fringe treatments. They are evidence-based applications of regenerative medicine for a condition that has been historically under-treated and misunderstood. The bladder can heal. The inflammation can calm. The cycle can break.

To learn more about how Integral Medicine approaches bladder health and regenerative therapies, visit our page on the science behind our protocols. If you are ready to explore whether PRP and ozone are right for your specific case, schedule a consultation at sarasotabradentonacupuncuture.com to discuss a personalized regenerative protocol. Relief does not have to mean simply coping. It can mean repairing.

941-444-6336 Directions